The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
C9orf72 intermediate expansions of 24–30 repeats are associated with ALS
Open accessAbstract
The expansion of a hexanucleotide repeat GGGGCC in C9orf72 is the most common known cause of ALS accounting for ~ 40% familial cases and ~ 7% sporadic cases in the European population. In most people, the repeat length is 2, but in people with ALS, hundreds to thousands of repeats may be observed. A small proportion of people have an intermediate expansion, of the order of 20 to 30 repeats in size, and it remains unknown whether intermediate expansions confer risk of ALS in the same way that massive expansions do. We investigated the association of this intermediate repeat with ALS by performing a meta-analysis of four previously published studies and a new British/Alzheimer’s Disease Neuroimaging Initiative dataset of 1295 cases and 613 controls. The final dataset comprised 5071 cases and 3747 controls. Our meta-analysis showed association between ALS and intermediate C9orf72 repeats of 24 to 30 repeats in size (random-effects model OR = 4.2, 95% CI = 1.23–14.35, p -value = 0.02). Furthermore, we showed a different frequency of the repeat between the northern and southern European populations (Fisher’s exact test p -value = 5 × 10 − 3 ). Our findings provide evidence for the association between intermediate repeats and ALS ( p -value = 2 × 10 − 4 ) with direct relevance for research and clinical practice by showing that an expansion of 24 or more repeats should be considered pathogenic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Repeats of 24 or more hexanucleotides in C9orf72 are considered pathogenic, leading to earlier diagnosis of ALS.
“Repeats of 24 or more hexanucleotides are considered pathogenic, leading to earlier diagnosis of ALS [6, 7].”
From Lifestyle and medical conditions in relation to ALS risk and progression—an introduction to the Swedish ALSrisc Study (2024) · cites this paper as [6]
The Discussion (page unavailable) proposes treating C9orf72 expansions of 24 or more repeats as pathogenic. The paper does not report that this threshold leads to earlier ALS diagnosis; its clinical analysis concerns age at onset and survival, not diagnostic timing. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
Amyotrophic lateral sclerosis: moving towards a new classification system
Al-Chalabi, A., Hardiman, O., Kiernan, M. C., Chiò, A., Rix-Brooks, B., & van den Berg, L. H. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30199-5 · Cited by 390
Self-citation
Flagged first, then by citations
Research works printed but not linked: 30
- Chiò A, Logroscino G, Traynor B, Collins J, Simeone J, Goldstein L, White L (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118–130 · DOI · Paper page
- Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH-M, Butt D, Ampong M-A, Shaw CE, Leigh PN, Al-Chalabi A (2006) Amyotrophic lateral sclerosis in an urban setting. J Neurol 253:1642–1643 · DOI
- Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 14:248 · DOI · Paper page
- Morita M, Al-Chalabi A, Andersen P, Hosler B, Sapp P, Englund E, Mitchell J, Habgood J, De Belleroche J, Xi J (2006) A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66:839–844 · DOI
- Shatunov A, Mok K, Newhouse S, Weale ME, Smith B, Vance C, Johnson L, Veldink JH, van Es MA, van den Berg LH (2010) Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. The Lancet Neurology 9:986–994 · DOI
- van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, Lemmens R, Schelhaas HJ, Groen EJ, Huisman MH (2009) Genome-wide association study identifies 19p13. 3 (UNC13A) and 9p21. 2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 41:1083 · DOI
- Vance C, Al-Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J, Siddique T, Schelhaas HJ, Kusters B, Troost D (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13. 2–21.3. Brain 129:868–876 · DOI
- Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C (2017) Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev 44:117–124 · DOI
- Byrne S, Heverin M, Elamin M, Walsh C, Hardiman O (2014) Intermediate repeat expansion length in C9orf72 may be pathological in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15:148–150 · DOI
- García-Redondo A, Dols-Icardo O, Rojas-García R, Esteban-Pérez J, Cordero-Vázquez P, Muñoz-Blanco JL, Catalina I, González-Muñoz M, Varona L, Sarasola E (2013) Analysis of the C 9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum Mutat 34:79–82 · DOI · Paper page
- Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, Janssens J, Bettens K, Van Cauwenberghe C, Pereson S (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. The Lancet Neurology 11:54–65 · DOI
- Millecamps S, Boillée S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, Moigneu C, Vandenberghe N, Danel-Brunaud V, Corcia P (2012) Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 49:258–263 · DOI
- Ratti A, Corrado L, Castellotti B, Del Bo R, Fogh I, Cereda C, Tiloca C, D’Ascenzo C, Bagarotti A, Pensato V (2012) C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. Neurobiol Aging 33:2528. e2527–2528. e2514 · DOI
- Chen Y, Lin Z, Chen X, Cao B, Wei Q, Ou R, Zhao B, Song W, Wu Y, Shang H-F (2016) Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging 38:217. e215–217. e222 · DOI
- Sutton AJ, Abrams KR, Jones DR, Jones DR, Sheldon TA, Song F (2000) Methods for meta-analysis in medical research
- Ioannidis JP (2007) Non-replication and inconsistency in the genome-wide association setting. Hum Hered 64:203–213 · DOI
- Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001) Replication validity of genetic association studies. Nat Genet 29:306 · DOI
- Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chiò A, Restagno G, Nicolaou N, Simon-Sanchez J (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. The Lancet Neurology 11:323–330 · DOI · Paper page
- Rutherford NJ, Heckman MG, DeJesus-Hernandez M, Baker MC, Soto-Ortolaza AI, Rayaprolu S, Stewart H, Finger E, Volkening K, Seeley WW (2012) Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging 33:2950. e2955–2950. e2957
- Gavaghan DJ, Moore RA, McQuay HJ (2000) An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain 85:415–424 · DOI
- Jackson D (2006) The power of the standard test for the presence of heterogeneity in meta-analysis. Stat Med 25:2688–2699 · DOI
- Consortium PMAS (2018) Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet 26:1537 · DOI
- van der Spek RA, van Rheenen W, Pulit SL, Kenna KP, McLaughlin RL, Moisse M, Dekker AM, Tazelaar GH, Kenna B, van Eijk KR (2018) The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. bioRxiv:377911
- Dolzhenko E, van Vugt JJ, Shaw RJ, Bekritsky MA, van Blitterswijk M, Narzisi G, Ajay SS, Rajan V, Lajoie B, Johnson NH (2017) Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome research: gr. 225672.225117 · DOI · Paper page
- Tazelaar GH, Dekker AM, van Vugt JJ, van der Spek RA, Westeneng H-J, Kool LJ, Kenna KP, van Rheenen W, Pulit SL, McLaughlin RL (2018) Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort. Neurobiology of Aging. · DOI
- Schwarzer G (2007) Meta: an R package for meta-analysis. R news 7:40–45
- Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S, Martindale J, Hartley J, Walsh T, Gelsthorpe C (2012) Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135:751–764 · DOI
- Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K (2013) Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 84:163–169 · DOI
- Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Al Khleifat A, Smith BN, Topp S, Morrison KE, Shaw PJ (2019) Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry 90:268–271 · DOI
- Stewart H, Rutherford NJ, Briemberg H, Krieger C, Cashman N, Fabros M, Baker M, Fok A, DeJesus-Hernandez M, Eisen A et al (2012) Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol 123:409–417. https://doi.org/10.1007/s00401-011-0937-5 · DOI
Cited by
Sorted by citations
Approaches to gene modulation therapy for ALS
Meijboom, K. E., & Brown, R. H. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01285-w · Cited by 38
Chourpiliadis, C., Seitz, C., Lovik, A., Joyce, E. E., Pan, L., Hu, Y., Kläppe, U., Samuelsson, K., Press, R., Ingre, C., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12496-w · Cited by 10
“Repeats of 24 or more hexanucleotides are considered pathogenic, leading to earlier diagnosis of ALS [6, 7].”
Background
Metadata
- Authors
- Initiative, A. D. N., Iacoangeli, A., Al Khleifat, A., Jones, A. R., Sproviero, W., Shatunov, A., Opie-Martin, S., Morrison, K. E., Shaw, P. J., Shaw, C. E., Fogh, I., Dobson, R. J., Newhouse, S. J., & Al-Chalabi, A.
- Affiliations
- San Francisco VA Medical Center (US)
- King's College London (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- Corresponding author
- Iacoangeli, Alfredo
- ORCID
- Venue
- Acta Neuropathologica Communications
- Published
- 2019-07-17
- Volume
- 7
- Issue
- 1
- Pages
- 115-115
- ISSN
- 2051-5960 (ISSN-L)
- PMC
- PMC6637621
- OpenAlex
- W2957790560
- Cited by
- 102
- References
- 4
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 17 · 2023: 15 · 2022: 17 · 2021: 17 · 2020: 17
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Acta Neuropathologica Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Research Portal (Queen's University Belfast) (submittedVersion, cc-by)
- Funders
- Motor Neurone Disease Association
- Medical Research Council (MR/L501529/1, MR/R024804/1)
- Economic and Social Research Council (ES/L008238/1)
- Horizon 2020 Framework Programme (633413)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- C9orf72, hexanucleotide repeat expansion, amyotrophic lateral sclerosis, ALS risk
- MeSH terms
- Whole Genome Sequencing, C9orf72 Protein, Aged, Amyotrophic Lateral Sclerosis, Female, Humans, Male, Middle Aged, Databases, Genetic, DNA Repeat Expansion, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review